Inflammation  >>  Imjudo (tremelimumab)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imjudo (tremelimumab) / AstraZeneca, Pfizer
NCT00897312: Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

Terminated
N/A
7
US
infliximab, Remicade, pegylated interferon alfa, pegylated interferon-a, ticilimumab, CP-675206, ribavirin, Copegus, Rebetol, Ribasphere, high performance liquid chromatography, not noted, laboratory biomarker analysis
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Melanoma
08/08
08/08
MITRE, NCT04107168: Microbiome Immunotherapy Toxicity and Response Evaluation

Recruiting
N/A
1800
Europe
Nivolumab, Opdivo, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Durvalumab, Imfinzi, Tremelimumab, CP-675,206, Atezolizumab, Tecentriq, Bevacizumab, Avastin
CCTU- Cancer Theme, Microbiotica Ltd
Melanoma, Renal Cancer, Lung Cancer
07/24
07/25

Download Options